These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 13582532)

  • 21. The utility of partial cross-over designs in early phase randomized prevention trials.
    Hutson AD; Reid ME
    Control Clin Trials; 2004 Oct; 25(5):493-501. PubMed ID: 15465618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoscopic subcutaneous mastectomy for the treatment of gynecomastia: a report of 65 cases.
    Fan L; Yang X; Zhang Y; Jiang J
    Surg Laparosc Endosc Percutan Tech; 2009 Jun; 19(3):e85-90. PubMed ID: 19542836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin.
    Contreras LN; Arregger AL; Persi GG; Gonzalez NS; Cardoso EM
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):675-82. PubMed ID: 15579180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of adrenal function using the human corticotrophin-releasing hormone test, low dose Synacthen test and 9am cortisol level in children and adolescents with central adrenal insufficiency.
    Maguire AM; Biesheuvel CJ; Ambler GR; Moore B; McLean M; Cowell CT
    Clin Endocrinol (Oxf); 2008 May; 68(5):683-91. PubMed ID: 18070143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of an enzyme-linked immunosorbent assay for fentanyl and applications of fentanyl antibody-coated nanoparticles for sample preparation.
    Mao CL; Zientek KD; Colahan PT; Kuo MY; Liu CH; Lee KM; Chou CC
    J Pharm Biomed Anal; 2006 Jun; 41(4):1332-41. PubMed ID: 16621415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
    Kang HN; Kim SN; Lee SH; Hong SH
    Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design.
    Park T; Ki M; Yi SG
    Stat Med; 2004 Jun; 23(12):1871-83. PubMed ID: 15195321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of duration of activity of corticotrophin-gelatin and corticotrophin-carboxymethylcellulose.
    Friedman M
    Br Med J; 1967 Aug; 3(5562):409-10. PubMed ID: 20791303
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of corticotrophin and of the corticoids on human skin].
    MANCINI RE; STRINGA SG; CANEPA L
    C R Seances Soc Biol Fil; 1956; 150(11):2021-2. PubMed ID: 13427306
    [No Abstract]   [Full Text] [Related]  

  • 32. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
    Danson S; Ranson M; Denneny O; Cummings J; Ward TH
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The subcutaneous assay of corticotrophin A. III. A cross-over design using a corticotrophin A standard preparation].
    RERUP C
    Acta Endocrinol (Copenh); 1958 Sep; 29(1):70-82. PubMed ID: 13582532
    [No Abstract]   [Full Text] [Related]  

  • 34. Omega-3 status and cerebrospinal fluid corticotrophin releasing hormone in perpetrators of domestic violence.
    Hibbeln JR; Bissette G; Umhau JC; George DT
    Biol Psychiatry; 2004 Dec; 56(11):895-7. PubMed ID: 15576068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficiency of the cross-over design: an empirical estimation.
    Garcia R; Benet M; Arnau C; Cobo E
    Stat Med; 2004 Dec; 23(24):3773-80. PubMed ID: 15580599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The bioassay of corticotrophin A; with special regard to the effect after subcutaneous administration.
    RERUP C
    Acta Endocrinol Suppl (Copenh); 1958; 29(Supp 42):1-20. PubMed ID: 13605556
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.